Laboratorios Farmaceuticos ROVI

Laboratorios Farmaceuticos ROVI Diluted EPS

The Diluted Earnings per Share of Laboratorios Farmaceuticos ROVI (ROVI.MC) as of Oct 27, 2026 is 2.75 EUR. In the previous year, Diluted Earnings per Share was 2.68 EUR — a change of 2.55% (higher).

Diluted EPS

2.75EUR

YoY

2.55%

Last updated:

Diluted Earnings per Share of Laboratorios Farmaceuticos ROVI is 2025 2.75 EUR. Diluted Earnings per Share of Laboratorios Farmaceuticos ROVI was 2024 2.68 EUR. It decreases by 2.55% higher compared to the previous year.

The Laboratorios Farmaceuticos ROVI Diluted EPS history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Diluted EPS
Date
Diluted EPS
Jan 1, 2018
0.32 EUR
Jan 1, 2019
0.71 EUR
Jan 1, 2020
1.10 EUR
Jan 1, 2021
2.84 EUR
Jan 1, 2022
3.74 EUR
Jan 1, 2023
3.29 EUR
Jan 1, 2024
2.68 EUR
Jan 1, 2025
2.75 EUR
The Laboratorios Farmaceuticos ROVI Diluted EPS history
YEARDiluted EPSYoY
2.75EUR+2.55%
2.68EUR-18.55%
3.29EUR-12.14%
3.74EUR+31.75%
2.84EUR+157.61%
1.10EUR+55.44%
0.71EUR+119.47%
0.32EUR-7.57%
0.35EUR-33.97%
0.53EUR+31.81%
0.40EUR-17.23%
0.49EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Laboratorios Farmaceuticos ROVI Stock analysis

What does Laboratorios Farmaceuticos ROVI do? Laboratorios Farmaceuticos ROVI SA is a Spanish pharmaceutical company that was founded in 1946 by Salvador and Ignacio Ruiz-Salmones. The company is headquartered in Madrid and employs over 1,000 employees. ROVI manufactures a variety of pharmaceutical products and offers services in various areas. The company specializes in the development and manufacturing of specialty preparations in the fields of oncology, hematology, endocrinology, and gastroenterology. The company operates in three business areas: specialty pharmaceuticals, contrast agents, and active ingredients for the industry. The specialty pharmaceuticals business area includes medications for various applications, such as the treatment of cancer, blood disorders, endocrine disorders, gastroenterological disorders, and central nervous system disorders. The contrast agents division produces products for radiology and diagnostics. The products are used in various medical fields, from cardiology to gastroenterology. In the active ingredients for the industry business area, ROVI manufactures active ingredients for other pharmaceutical companies. ROVI specializes in the production of specialty products and relies on collaborations with other companies. The company has strategic partnerships with many companies such as GlaxoSmithKline, Pfizer, Sanofi-Aventis, and Zeltia. This also includes some research collaborations to develop and market products together. The company is also dedicated to the development of biosimilars, which allow for the offering of biologic drugs at a lower price. Biosimilars are copies of biopharmaceuticals that are usually very expensive due to the complex manufacturing process and high development costs. ROVI is also a major producer of vaccines that are distributed worldwide. ROVI has followed a solid growth trajectory in recent years. The company has been able to consistently increase its revenue and profit and is now a major player in the pharmaceutical industry. The company also operates a strong research and development department that constantly develops new products and technologies to improve patient care. In summary, Laboratorios Farmaceuticos ROVI SA is a leading pharmaceutical company specializing in the manufacturing of specialty products. With its subsidiaries in Europe and the USA, ROVI has an international presence and has made a name for itself through its expertise in the development and manufacturing of innovative pharmaceutical products. Laboratorios Farmaceuticos ROVI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Laboratorios Farmaceuticos ROVI stock

Diluted Earnings per Share of Laboratorios Farmaceuticos ROVI is 2.75 EUR in 2025.

Diluted Earnings per Share of Laboratorios Farmaceuticos ROVI changed from 2.68 EUR to 2.75 EUR, representing a 2.55% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Diluted Earnings per Share Laboratorios Farmaceuticos ROVI since 2006 – with annual values, charts, and detailed analysis.

Diluted EPS accounts for all potential shares from options, warrants, and convertible securities. It provides a more conservative per-share earnings measure.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Laboratorios Farmaceuticos ROVI

All Key Metrics — Laboratorios Farmaceuticos ROVI